Compare Bristol-Myers Squibb Co (BMY) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs SiTime Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while SiTime Corporation trades at $611.1 (market cap $18.72B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.2× SiTime Corporation's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| BMY | SITM | |
|---|---|---|
Market Cap | $116.30B | $18.72B |
Sector | Health | Technology |
52-Week High | $62.37 | $901.60 |
52-Week Low | $42.60 | $190.16 |
Enterprise Value | $152.24B | $17.93B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
SITM trades at $602.55, down 4.2% over 24 hours, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth and expanding gross margins, driven by AI infrastructure demand and the completed Renesas acquisition. Analyst consensus remains unanimously bullish with a $743.75 price target, though negative net income and high valuation ratios present fundamental concerns.
Outlook is mixed: robust AI-driven growth and strategic acquisitions offer upside, but profitability challenges and bearish technicals near-term pose risks. Investors should weigh strong analyst support against cash flow volatility and execution risks in integrating new assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
